Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin + Paclitaxel + Bevacizumab in Platinum-resistant Ovarian Cancer
NCT05636111Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2023
- Primary completion
- Dec 2026
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lurbinectedin in ovarian cancer, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of Adverse Events at 1 year and Dose-limiting toxicities at 1 year. Started Jul 2023; status: recruiting.
02
Drugs
lurbinectedin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05636111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05636111.